2003
DOI: 10.1053/sonc.2003.50016
|View full text |Cite
|
Sign up to set email alerts
|

Surgical treatment of small cell lung cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
8
0
2

Year Published

2004
2004
2020
2020

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 27 publications
(10 citation statements)
references
References 49 publications
0
8
0
2
Order By: Relevance
“…These studies were criticized for including only central tumours and for not using either tomography or mediastinoscopy in the staging. In addition, in the former, many of the patients studied would not be operable with current criteria, and the intraoperative staging did not require radical mediastinal lymphadenectomy, while in the second, stages T1-T2 N0 were specifically excluded [23,24]. In the early 1990s, two meta-analysis [25,26] confirmed that adding thoracic RT to CT significantly improved long term survival for patients with limited disease.…”
Section: Discussionmentioning
confidence: 80%
“…These studies were criticized for including only central tumours and for not using either tomography or mediastinoscopy in the staging. In addition, in the former, many of the patients studied would not be operable with current criteria, and the intraoperative staging did not require radical mediastinal lymphadenectomy, while in the second, stages T1-T2 N0 were specifically excluded [23,24]. In the early 1990s, two meta-analysis [25,26] confirmed that adding thoracic RT to CT significantly improved long term survival for patients with limited disease.…”
Section: Discussionmentioning
confidence: 80%
“…This is the group of patients who are most reported to benefit from a surgical addition to multimodality treatment [19]. There are also clear indications that in a small percentage of slow-growing, peripheral and resectable SCLC surgery may give unusually good results [20].…”
Section: Discussionmentioning
confidence: 99%
“…Combined chemotherapy and radiotherapy has become an accepted standard for the management of patients with locally advanced unresectable non-small cell lung cancer (stage IIIB and some stage IIIA). [1][2][3] To date an optimal dosage, schedule and duration of therapy has not been determined, but better results are observed when platinum-based chemotherapy is used, 4-6 radiation dosages of 60 Gy in 6 weeks or biologically equivalent schedules are used, 7,8 and when at least some component of the radiation and chemotherapy is given concurrently. 9 In 1997 we commenced a pilot study to assess the efficacy and tolerability of induction chemotherapy with two cycles of cisplatin and gemcitabine followed by definitive local treatment for IIIA and IIIB non-small cell lung cancer.…”
Section: Introductionmentioning
confidence: 99%